Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
ORTHO CYCLEN-28 is an oral contraceptive tablet combining norgestimate and ethinyl estradiol, approved in 1989 as a combination hormonal birth control product. It is indicated for contraception in women of reproductive age. The drug works by suppressing ovulation through hormonal mechanisms.
Product approaching loss of exclusivity with moderate competitive pressure (30), likely operating with a lean, defensive team focused on retention and compliance.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ORTHO CYCLEN-28 offers limited career advancement opportunities given the product's mature stage and approaching loss of exclusivity. This role is best suited for professionals focused on defensive commercial strategy, generic transition planning, or compliance management rather than innovation-driven growth.
Worked on ORTHO CYCLEN-28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.